We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Indivior Plc | INDV | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 14.00 | 0.93% | 1,520.00 | 16:35:23 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1,506.00 | 1,480.00 | 1,515.00 | 1,520.00 | 1,506.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 23/4/2024 14:49 by gregmorg Well Dealy,Overall you may well be right re US valuations versus UK valuations. Certainly, David Schwimmer CEO of LSEG Group Plc (of which the London Stock Exchange is a small part) has also stated very similar sentiment. However, this hasn't stopped the UK media( plus others) and many UK companies and senior executives indicating otherwise and expressing frustration,if not actually indicating they are actively looking at possible relocation. Obviously there can be several agenda's here , and that I accept. Unfortunately those intimately involved with markets seem not to be able to address the issues very well. Possibly, its just this stage we have reached within a normal stock market cycle although the bigger and more liquid market place argument is powerful. As an ordinary investor here I just find it very frustrating. |
Posted at 23/4/2024 10:03 by gregmorg Purely speculation on my part but I do wonder whether the change in listing status ,resulting in a lesser UK market status is causing a near term outflow of UK investors. What it does for Indivior's UK indices standing I just don't know. Maybe it also takes time for the US Nasdaq main listing investor base to develop let alone build up a US indices momentum .Hence little current forward optimism.Anything else well ,we will soon find out! The early half US Nasdaq additional listing has, of course, been a complete dud-- well, for the majority of investors anyway! At times I wonder what quality of capital markets advisers these chaps have-let alone in house stock market awareness! |
Posted at 22/2/2024 15:10 by casholaa In fairness to them, they've hived off money for the litigation so it doesn't distort net cash, they recognize that it's mainly a US market-driven company with mainly US investors, they are expanding globally, they are not a one-trick pony, they have been succeeding on the revenue front and return value to shareholders through buybacks for the time being.*they also pointed out that they only recently started sales through pharmacy/private doctor dispensers *global company in the making, we just happen to be poorer than our US counterparts |
Posted at 05/12/2023 16:08 by waldron Indivior PLC INDV Prevails in Striking Claims in UK Litigation (7595V)05/12/2023 2:06pm UK Regulatory (RNS & others) Tuesday 5 December 2023 TIDMINDV RNS Number : 7595V Indivior Prevails in Striking Representative Claims from UK Shareholder Action Richmond, VA and Slough UK, December 5, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, announced that the High Court of Justice of England and Wales has issued a judgment striking out representative claims by Wirral Council as administering authority of Merseyside Pension fund ("Wirral") against Indivior under the Financial Services and Markets Act 2000 ("FSMA"). Wirral's suit was the first attempt by claimants to use representative proceedings for securities claims brought under Sections 90, 90A, and Schedule 10 of the FSMA. The proposed representative proceedings, if allowed, would permit a representative acting on behalf of unnamed claimants to attempt to prove a violation of law without proof of damages, in contrast to ordinary multi-party proceedings, which require proof of liability and damages for each claimant. In September 2022, Wirral had filed a representative claim generally asserting that Indivior violated the FSMA by making misleading or dishonest statements regarding an alleged fraudulent scheme to switch the market for its SUBOXONE (R) branded products in published information relating to securities. A similar claim was filed against Reckitt Benckiser. After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings. The Court specifically found that it "would be unfair and unjust, and contrary to the overriding objective, to allow the Representative Proceedings to oust the jurisdiction of the Court to case manage the claims from the start." The Court's judgment may be found here . Wirral and other claimants separately had filed a multi-party action generally alleging the same claims, and levied similar allegations against Reckitt Benckiser Group PLC ("Reckitt Benckiser") in separate actions. Pursuant to the Court's judgment, the claim against Indivior may only proceed in those multi-party proceedings brought by the claimants named in those proceedings. Wirral may seek permission to appeal the Court's judgment. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/com This release is being made by Kathryn Hudson, Company Secretary Indivior PLC. Media Contacts : US Media : Cassie France-Kelly Vice President, Communications Indivior PLC Tel: 804-724-0327 UK Media : Teneo Tel: +44 207-353-4200 Investors and Analysts : Jason Thompson Vice President, Investor Relations Indivior PLC Tel: 804-402-7123 Tim Owens Director, Investor Relations Indivior PLC Tel: 804-263-3978 -ends- (END) Dow Jones Newswires December 05, 2023 09:06 ET (14:06 GMT) |
Posted at 09/11/2023 07:38 by ariane SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.Indivior (PRNewsfoto/Indivior The earnings release can be found at www.indivior.com/inv The investor presentation can be found at www.indivior.com/inv There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: Participants may access the presentation telephonically by registering with the following link: [...] |
Posted at 27/7/2023 09:01 by gregmorg I am afraid the market reaction is the never ending litigation issues and the way the company has spelt it out in the notes this time. Nothing has changed according to the company but investors are bound to run from comments such as these.I am dissappointed to see this given I remain a LT holder |
Posted at 30/5/2023 09:29 by steeplejack Perhaps on our demise (hopefully not before)some of the more active private investors will be stuffed and exhibited in a museum.I will keep a wary eye out for roaming taxidermists. |
Posted at 24/5/2023 06:47 by steeplejack Executives see the US as an environment that embraces higher growth, while they bemoan the lack of interest from UK-based investors in their home market, particularly pension funds that have increasingly shunned British stocks over the past two decades.“There are no domestic equity investors here — everything else is a symptom,” said Michael Tory, founder of advisory firm Ondra Partners. “It’s not about the listing rules, the governance or the free float requirements. Global investors look to domestic investors for the signal to validate the investment, and that local signal has simply flickered out.” |
Posted at 29/3/2023 13:58 by steeplejack Thereagain,GW Phamaceuticals abandoned AIM a few years back and listed on Nasdaq and was then taken over by Jazz Pharmaceuticals in 2021.Since MIFID2,research coverage for small,mediumUK companies (on the AIM market in particular) has diminished.Indivior is a FT250 constituent but it could well attract better research coverage in the USA and there are currency considerations.US funds might well be reticent to purchase sterling denominated stocks or pay UK government stamp duty for that matter.In any event,Indivior’ |
Posted at 07/12/2022 07:52 by grupo guitarlumber 07 December 2022Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook - Peak Annual Net Revenue Potential for SUBLOCADE (R) Increased to >$1.5 Billion - Attractive and Scalable Business Outlined - Expects Strong Net Revenue Growth and Operating Margin Expansion Over the Medium-term - Disciplined Approach to Capital Allocation Maintained - NASDAQ Listing Targeted for Spring 2023 This Release Contains Inside Information. Slough, UK, and Richmond, VA, December 7, 2022 - Indivior PLC (LON: INDV) will hold a Capital Markets Day today in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value. "We have made tremendous progress executing on our strategic priorities," said Mark Crossley. "We are the pioneer and global leader in addiction treatment and science and are well-positioned to transform the lives of the increasing number of patients affected by the opioid crisis, one of the most urgent public health emergencies of our time. Today, my team and I are excited to provide a deep review of our business and to highlight the compelling opportunities we have to innovate in the treatment of addiction and serious mental illness while delivering profitable growth and significant value creation for shareholders." -- Increases SUBLOCADE peak annual net revenue (NR) expectations to >$1.5 billion Indivior expects SUBLOCADE(R) (buprenorphine extended-release) injection to achieve a NR run rate of $1 billion by the end of 2025, driven by its focus on further developing the Organized Health Systems (OHS) channel and pursuing the large opportunity in the U.S. Justice System. Longer term, based on the expected positive market dynamics for buprenorphine medication-assisted treatment (BMAT) and on continued execution against its OHS strategy, Indivior now expects to deliver SUBLOCADE peak potential NR of >$1.5 billion. -- Expects to achieve attractive double-digit % NR compounded annual growth rate (CAGR) over the medium-term Indivior expects to achieve a double-digit percentage NR CAGR over the medium-term, driven primarily by SUBLOCADE in the United States and growing NR contribution from PERSERIS(R) (risperidone for extended-release injection). Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEX (R) PR) and SUBOXONE (R) (buprenorphine/nalox -- Operating margin expansion opportunity from scalable business model Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses. Following the significant structural growth investments behind SUBLOCADE and PERSERIS in the past two years, selling, general and administrative (SG&A) expenses are expected to grow at a more moderate pace and to decline as a percentage of NR. This impact is expected to be partly offset by an increase in R&D expenses as a percentage of NR towards industry benchmarks as the Company seeks to build a strong and balanced pipeline focused on addiction treatments. -- Disciplined capital allocation approach focused on driving growth and potential returns of excess cash In the past two years, Indivior's healthy balance sheet and improved cash flow have supported a balanced approach towards capital allocation, focused on investment in key growth priorities, diversifying the business, delivering shareholder returns and meeting other stakeholder obligations. The recently announced definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) is indicative of Indivior's commitment to diversify its product portfolio and to expand its global leadership in addiction treatment and science. -- Listing on NASDAQ targeted for the Spring of 2023 At its Extraordinary General Meeting (EGM) in September of this year, Indivior received strong support from its shareholders for an additional share listing in the United States. Having carefully evaluated the available options, Indivior has chosen NASDAQ as its U.S. trading venue. The additional listing is expected to elevate Indivior's profile in the Company's largest market and to attract a broader group of biopharma-focused investors and analysts. The Group reiterates its FY 2022 guidance published on October 27, 2022. Event Details Today's event will begin at 8:30am EST and conclude at 12:30pm EST. Due to limited availability, in-person participation is limited to institutional investors and analysts. For those wishing to attend in person, please RSVP to investorrelations@in Further details can be found at cmd.indivior.com To access the live webcast, please click INDV CMD 2022 . A webcast replay will be available after the event has concluded. The person responsible for making this announcement is Kathryn Hudson, Company Secretary. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
